Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy
Diabetes, Obesity and Metabolism, 06/04/2012
Kimura S et al. – Pitavastatin is more effective than pravastatin for the reduction of albuminuria in type 2 diabetic patients with early stage of diabetic nephropathy.Methods
- The effect of pitavastatin and pravastatin treatment on renal function was compared in type 2 diabetic patients with nephropathy in a randomized, controlled, open–label, parallel and multi–centre study.
- Type 2 diabetic patients with modest renal impairment (serum creatinine level <1.4 mg/dl) accompanied by albuminuria (30–600 mg/g creatinine) were randomly assigned to receive 2 mg of pitavastatin (n = 44) or 10 mg of pravastatin (n = 43) for 12 months.
- At 12 months, pitavastatin significantly reduced urinary albumin–to–creatinine ratio than pravastatin in subjects with macroalbuminuria (–67.2% vs. +14.5%, p = 0.0040), but not in subjects with microalbuminuria.
- There was no significant difference in the change in estimated glomerular filtration rate between the two groups.